Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816026 | 1.00 | OPRK1 (0.48) | OPRK1ABL1SERPINH1NR4A2SLC6A4 | |
| SCHEMBL26660324 | 0.84 | CA12 (0.49) | ABL1SERPINH1ALDH1A1KDM4EGAA | |
| SCHEMBL3732128 | 0.84 | ATM (0.47) | OPRK1ABL1SERPINH1ALDH1A1KDM4E | |
| SCHEMBL31368194 | 0.84 | CA12 (0.49) | ABL1SERPINH1ALDH1A1KDM4EGAA | |
| SCHEMBL3520084 | 0.84 | MAPK1 (0.47) | ABL1ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL401530 | 0.84 | OPRK1 (0.47) | OPRK1ABL1SERPINH1NR4A2SLC6A4 | |
| SCHEMBL1854140 | 0.82 | MKNK1 (0.43) | ABL1NR4A2 | |
| SCHEMBL10473574 | 0.82 | OPRK1 (0.46) | OPRK1ABL1SERPINH1NR4A2SLC6A4 | |
| SCHEMBL21462378 | 0.82 | OPRK1 (0.46) | OPRK1ABL1SERPINH1NR4A2SLC6A4 | |
| SCHEMBL19682934 | 0.82 | KDR (0.49) | OPRK1ABL1SERPINH1NR4A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115630-A1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| US-12180233-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-12-31 | — | — | US | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113383002-B | Mononuclear iridium complex containing three orthometalated bidentate ligands and having optically directional anisotropy | UDC爱尔兰有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-113272293-B | 2-Amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-111699192-B | Metal complex | UDC爱尔兰有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| CN-1098843-C | Isoxazoles | SANKYO CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| CN-1162957-A | Isoxazole derivatives | SANKYO CO (JP) | 1997-10-22 | — | — | CN | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| US-5118680-A | COMBATING ENDOPARASITES WITH 3-HYDROXYBENZOTHIOPHENES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| EP-0403885-A1 | Utilization of 3-hydroxybenzothiophens for combatting endoparasites, new 3-hydroxythiophens and process for their preparation | BAYER AG (DE) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180233-B2 | Metal complexes | IMMT, MCU, SOD1 | OPRK1 1276/4885ABL1 2133/4885SERPINH1 3840/4885 |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | OPRK1 371/4885ABL1 1313/4885SERPINH1 1861/4885 |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | OPRK1 2869/4885ABL1 611/4885SERPINH1 3684/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | OPRK1 371/4885ABL1 1313/4885SERPINH1 1861/4885 |
| US-20250115630-A1 | METAL COMPLEXES | IMMT, MCU, SOD1 | OPRK1 1276/4885ABL1 2133/4885SERPINH1 3840/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | OPRK1 1507/4885ABL1 2388/4885SERPINH1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.